Peer-influenced content. Sources you trust. No registration required. This is HCN.
Modern Optometry
As we embrace the era of antibody-drug conjugates (ADCs) in cancer therapy, it’s crucial to understand their impact on ocular health. With ADCs like mirvetuximab offering new hope for ovarian cancer patients, effective partnerships between optometrists and oncologists are key to managing associated ocular adverse events.
Optometry October 30th 2023
The New England Journal of Medicine
Explore the intricate relationship between stem cell self-renewal and precancer states to better understand its implications for future cancer therapies
Hematology/Oncology October 9th 2023
MDLinx
Discover how mechanoresilient cancer cells evade the body’s natural defenses and what this means for the future of targeted cancer therapies.
Hematology/Oncology October 2nd 2023
Ophthalmology Advisor
Understanding the ocular side effects of targeted cancer therapies is crucial. Early monitoring and interdisciplinary communication can significantly impact treatment outcomes.
Ophthalmology September 26th 2023
Clinical Advances in Hematology & Oncology
Explore the intricacies of diagnosing and treating acral melanoma, a subtype that presents unique challenges but also offers new avenues for targeted therapies and immune modulation.
Oncology, Medical August 28th 2023
Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.